See more : StateHouse Holdings Inc. (STHZ.CN) Income Statement Analysis – Financial Results
Complete financial analysis of Zhejiang Tianyu Pharmaceutical Co., Ltd. (300702.SZ) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Zhejiang Tianyu Pharmaceutical Co., Ltd., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Zug Estates Holding AG (0QPW.L) Income Statement Analysis – Financial Results
- GeeCee Ventures Limited (GEECEE.NS) Income Statement Analysis – Financial Results
- Vakrangee Limited (VAKRANGEE.BO) Income Statement Analysis – Financial Results
- Mitsuchi Corporation (3439.T) Income Statement Analysis – Financial Results
- Experience Co Limited (EXP.AX) Income Statement Analysis – Financial Results
Zhejiang Tianyu Pharmaceutical Co., Ltd. (300702.SZ)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.tianyupharm.com
About Zhejiang Tianyu Pharmaceutical Co., Ltd.
Zhejiang Tianyu Pharmaceutical Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical intermediates and APIs in China and internationally. The company offers pharmaceutical intermediates and APIs of cardiovascular, anti-diabetic, anti-atherosclerosis, anticoagulant, and anti-asthmatic series. It also provides fine chemicals and CMO services. The company was founded in 1993 and is based in Taizhou, China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.53B | 2.67B | 2.55B | 2.59B | 2.11B | 1.47B | 1.19B | 1.08B | 840.09M | 777.35M | 723.25M |
| Cost of Revenue | 1.54B | 1.98B | 1.61B | 1.25B | 926.40M | 876.27M | 739.07M | 677.00M | 563.54M | 556.78M | 522.33M |
| Gross Profit | 990.05M | 687.54M | 932.81M | 1.34B | 1.18B | 590.69M | 449.21M | 405.34M | 276.55M | 220.57M | 200.92M |
| Gross Profit Ratio | 39.17% | 25.78% | 36.65% | 51.65% | 56.11% | 40.27% | 37.80% | 37.45% | 32.92% | 28.37% | 27.78% |
| Research & Development | 243.82M | 231.10M | 227.40M | 179.07M | 112.25M | 79.46M | 59.21M | 58.73M | 41.41M | 31.08M | 32.74M |
| General & Administrative | 95.46M | 126.51M | 139.85M | 105.08M | 115.77M | 93.49M | 71.03M | 55.81M | 47.97M | 36.52M | 133.91M |
| Selling & Marketing | 83.29M | 47.43M | 32.20M | 33.34M | 43.54M | 37.47M | 27.05M | 25.53M | 23.43M | 22.00M | 17.78M |
| SG&A | 178.75M | 173.94M | 172.05M | 138.42M | 159.31M | 130.96M | 98.08M | 81.34M | 71.40M | 58.53M | 151.69M |
| Other Expenses | 496.73M | -8.67M | -21.67M | -6.87M | 7.79M | -23.18M | -1.19M | 8.23M | 4.69M | -411.25K | 18.96M |
| Operating Expenses | 919.30M | 647.12M | 697.12M | 579.85M | 476.97M | 361.81M | 276.40M | 253.97M | 208.09M | 167.38M | 157.77M |
| Cost & Expenses | 2.46B | 2.63B | 2.31B | 1.83B | 1.40B | 1.24B | 1.02B | 930.97M | 771.63M | 724.15M | 680.10M |
| Interest Income | 6.07M | 7.22M | 10.05M | 4.11M | 3.21M | 3.03M | 2.60M | 1.99M | 2.68M | 1.91M | 0.00 |
| Interest Expense | 51.24M | 33.85M | 16.33M | 4.41M | 12.19M | 19.38M | 22.88M | 22.22M | 24.69M | 21.22M | 22.60M |
| Depreciation & Amortization | 305.13M | 255.98M | 193.98M | 136.76M | 104.32M | 84.81M | 77.91M | 12.41M | 51.32M | 41.99M | 23.43M |
| EBITDA | 426.95M | 187.14M | 432.00M | 911.46M | 801.65M | 291.47M | 221.47M | 179.42M | 95.35M | 89.87M | 43.15M |
| EBITDA Ratio | 16.89% | 11.28% | 18.52% | 33.94% | 38.52% | 20.92% | 20.22% | 21.43% | 16.55% | 12.41% | 6.05% |
| Operating Income | 145.84M | -101.83M | 240.08M | 775.75M | 688.31M | 195.75M | 119.89M | 137.79M | 55.95M | 26.55M | 20.35M |
| Operating Income Ratio | 5.77% | -3.82% | 9.43% | 29.98% | 32.61% | 13.34% | 10.09% | 12.73% | 6.66% | 3.42% | 2.81% |
| Total Other Income/Expenses | -68.70M | -30.83M | -21.67M | -6.87M | -4.21M | -26.23M | -37.61M | 5.53M | 4.05M | -22.39M | 18.71M |
| Income Before Tax | 77.13M | -110.50M | 218.41M | 768.88M | 684.10M | 189.30M | 118.70M | 143.32M | 59.99M | 26.66M | 39.06M |
| Income Before Tax Ratio | 3.05% | -4.14% | 8.58% | 29.72% | 32.41% | 12.90% | 9.99% | 13.24% | 7.14% | 3.43% | 5.40% |
| Income Tax Expense | 44.56M | 8.45M | 13.73M | 101.82M | 98.38M | 25.64M | 18.51M | 20.98M | 9.64M | 2.52M | 5.47M |
| Net Income | 27.36M | -118.95M | 204.68M | 667.06M | 585.73M | 163.66M | 100.18M | 122.34M | 50.35M | 24.14M | 33.59M |
| Net Income Ratio | 1.08% | -4.46% | 8.04% | 25.78% | 27.75% | 11.16% | 8.43% | 11.30% | 5.99% | 3.11% | 4.64% |
| EPS | 0.08 | -0.34 | 0.59 | 2.06 | 1.80 | 0.51 | 0.38 | 0.51 | 0.21 | 0.10 | 0.14 |
| EPS Diluted | 0.08 | -0.34 | 0.59 | 2.05 | 1.79 | 0.51 | 0.38 | 0.51 | 0.21 | 0.10 | 0.14 |
| Weighted Avg Shares Out | 341.99M | 345.57M | 346.91M | 323.82M | 325.57M | 323.73M | 261.34M | 241.54M | 241.44M | 240.07M | 243.75M |
| Weighted Avg Shares Out (Dil) | 341.99M | 345.57M | 346.91M | 325.40M | 327.42M | 323.73M | 261.34M | 241.54M | 241.44M | 240.07M | 243.75M |
Source: https://incomestatements.info
Category: Stock Reports